United Therapeutics To Price Oral Treprostinil On Par With Other Formulations
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA labeling for just-approved pulmonary arterial hypertension drug Orenitram (treprostinil) suggests the oral drug could replace United Therapeutics’ other formulations, though it was not specifically studied for that. Company says it was surprised by the approval, which came well ahead of the user fee date, and plans to launch in six months.
You may also be interested in...
Earnings Updates, In Brief: Alkermes, Celldex, Jazz, United Therapeutics, Bayer
Alkermes discontinues development of a Phase I pain drug but is on track with schizophrenia drug launch; Celldex gains “breakthrough” designation for rindopepimut; Jazz halts a mid-stage trial due to safety issues; United Therapeutics talks up PAH drug; and Bayer CEO slams German government for lack of VC support.
FDA Pulmonary Hypertension Patient Meeting Follows Two Recent Approvals
In announcing the May 13 meeting, FDA asks whether pulmonary arterial hypertension medications have made a difference to patients with the condition.
Street Unsurprised By CRL For Oral Treprostinil, But United Therapeutics’ Stock Tumbles Anyway
A “complete response” letter from FDA to United’s December NDA for solo therapy of PAH with oral treprostinil certainly will delay and may endanger the Maryland firm’s best near-term growth driver.